Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics

Vance G Nielsen, James K. Kirklin, Hugh Hoogendoorn, Truitt C. Ellis, William L. Holman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Factor XIII (FXIII) plays a critical role in clot strength, and FXIII deficiency or excess is associated with hemorrhage or thrombosis, respectively. Our goal was to design a thrombelastography-based method to characterize the effects of FXIII on plasma clot strength. Normal human plasma was exposed to 0 or 200 μg/ml anti-FXIII antibodies for 20 min prior to celite activation and calcium addition. Other plasma had addition of fibrinogen (625 mg/dl)/FXIII (2 U/ml) or 30% dilution with hydroxyethyl starch before exposure to 0 or 200 μg/ml anti-FXIII antibodies. Thromboelastography was performed and data were collected until stable clot strength was observed. The exposure of normal plasma to anti-FXIII antibodies resulted in a significant (P < 0.05) decrease in clot strength (63%) compared with plasma without antibodies. Further samples exposed to anti-FXIII antibodies had clot strength no different from FXIII-deficient plasma. The FXIII-mediated clot strength varied between 44 and 50% in hypercoagulable and hypocoagulable plasma, respectively. In conclusion, the present investigation successfully demonstrated a novel method to detect the impact of FXIII activity in plasma samples. Further actuarial investigation will be required to determine the utility of this approach in the diagnosis and treatment of patients with either acquired FXIII deficiency or excess and concordant coagulopathy.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume18
Issue number2
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Factor XIII
Factor XIII Deficiency
Antibodies
Thrombelastography
Diatomaceous Earth
Starch
Fibrinogen
Thrombosis
Hemorrhage
Calcium

Keywords

  • Coagulation
  • Factor XIII
  • Measurement techniques
  • Thrombelastography

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics. / Nielsen, Vance G; Kirklin, James K.; Hoogendoorn, Hugh; Ellis, Truitt C.; Holman, William L.

In: Blood Coagulation and Fibrinolysis, Vol. 18, No. 2, 03.2007, p. 145-150.

Research output: Contribution to journalArticle

Nielsen, Vance G ; Kirklin, James K. ; Hoogendoorn, Hugh ; Ellis, Truitt C. ; Holman, William L. / Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics. In: Blood Coagulation and Fibrinolysis. 2007 ; Vol. 18, No. 2. pp. 145-150.
@article{e5ac0ab5fb4449bdaf779e398015c4f0,
title = "Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics",
abstract = "Factor XIII (FXIII) plays a critical role in clot strength, and FXIII deficiency or excess is associated with hemorrhage or thrombosis, respectively. Our goal was to design a thrombelastography-based method to characterize the effects of FXIII on plasma clot strength. Normal human plasma was exposed to 0 or 200 μg/ml anti-FXIII antibodies for 20 min prior to celite activation and calcium addition. Other plasma had addition of fibrinogen (625 mg/dl)/FXIII (2 U/ml) or 30{\%} dilution with hydroxyethyl starch before exposure to 0 or 200 μg/ml anti-FXIII antibodies. Thromboelastography was performed and data were collected until stable clot strength was observed. The exposure of normal plasma to anti-FXIII antibodies resulted in a significant (P < 0.05) decrease in clot strength (63{\%}) compared with plasma without antibodies. Further samples exposed to anti-FXIII antibodies had clot strength no different from FXIII-deficient plasma. The FXIII-mediated clot strength varied between 44 and 50{\%} in hypercoagulable and hypocoagulable plasma, respectively. In conclusion, the present investigation successfully demonstrated a novel method to detect the impact of FXIII activity in plasma samples. Further actuarial investigation will be required to determine the utility of this approach in the diagnosis and treatment of patients with either acquired FXIII deficiency or excess and concordant coagulopathy.",
keywords = "Coagulation, Factor XIII, Measurement techniques, Thrombelastography",
author = "Nielsen, {Vance G} and Kirklin, {James K.} and Hugh Hoogendoorn and Ellis, {Truitt C.} and Holman, {William L.}",
year = "2007",
month = "3",
doi = "10.1097/MBC.0b013e32802f7d91",
language = "English (US)",
volume = "18",
pages = "145--150",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics

AU - Nielsen, Vance G

AU - Kirklin, James K.

AU - Hoogendoorn, Hugh

AU - Ellis, Truitt C.

AU - Holman, William L.

PY - 2007/3

Y1 - 2007/3

N2 - Factor XIII (FXIII) plays a critical role in clot strength, and FXIII deficiency or excess is associated with hemorrhage or thrombosis, respectively. Our goal was to design a thrombelastography-based method to characterize the effects of FXIII on plasma clot strength. Normal human plasma was exposed to 0 or 200 μg/ml anti-FXIII antibodies for 20 min prior to celite activation and calcium addition. Other plasma had addition of fibrinogen (625 mg/dl)/FXIII (2 U/ml) or 30% dilution with hydroxyethyl starch before exposure to 0 or 200 μg/ml anti-FXIII antibodies. Thromboelastography was performed and data were collected until stable clot strength was observed. The exposure of normal plasma to anti-FXIII antibodies resulted in a significant (P < 0.05) decrease in clot strength (63%) compared with plasma without antibodies. Further samples exposed to anti-FXIII antibodies had clot strength no different from FXIII-deficient plasma. The FXIII-mediated clot strength varied between 44 and 50% in hypercoagulable and hypocoagulable plasma, respectively. In conclusion, the present investigation successfully demonstrated a novel method to detect the impact of FXIII activity in plasma samples. Further actuarial investigation will be required to determine the utility of this approach in the diagnosis and treatment of patients with either acquired FXIII deficiency or excess and concordant coagulopathy.

AB - Factor XIII (FXIII) plays a critical role in clot strength, and FXIII deficiency or excess is associated with hemorrhage or thrombosis, respectively. Our goal was to design a thrombelastography-based method to characterize the effects of FXIII on plasma clot strength. Normal human plasma was exposed to 0 or 200 μg/ml anti-FXIII antibodies for 20 min prior to celite activation and calcium addition. Other plasma had addition of fibrinogen (625 mg/dl)/FXIII (2 U/ml) or 30% dilution with hydroxyethyl starch before exposure to 0 or 200 μg/ml anti-FXIII antibodies. Thromboelastography was performed and data were collected until stable clot strength was observed. The exposure of normal plasma to anti-FXIII antibodies resulted in a significant (P < 0.05) decrease in clot strength (63%) compared with plasma without antibodies. Further samples exposed to anti-FXIII antibodies had clot strength no different from FXIII-deficient plasma. The FXIII-mediated clot strength varied between 44 and 50% in hypercoagulable and hypocoagulable plasma, respectively. In conclusion, the present investigation successfully demonstrated a novel method to detect the impact of FXIII activity in plasma samples. Further actuarial investigation will be required to determine the utility of this approach in the diagnosis and treatment of patients with either acquired FXIII deficiency or excess and concordant coagulopathy.

KW - Coagulation

KW - Factor XIII

KW - Measurement techniques

KW - Thrombelastography

UR - http://www.scopus.com/inward/record.url?scp=33846930612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846930612&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32802f7d91

DO - 10.1097/MBC.0b013e32802f7d91

M3 - Article

C2 - 17287631

AN - SCOPUS:33846930612

VL - 18

SP - 145

EP - 150

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 2

ER -